Tag Myelofibrosis

Ojjaara approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.  Ojjaara is…